Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

SPB Exchange summarized the results of trading in May

6/5/23 SPBE

VKontakte is developing an app for car tuning

6/5/23 VKCO

Shareholders of Moscow Exchange approved dividends for 2022

6/2/23 MOEX

Moscow Exchange summarized the results of trading in May

6/2/23 MOEX

Transneft will build an oil pumping station to increase shipments to the east

6/2/23 TRNFP

Board of Directors of Rushydro recommended that dividends be paid for 2022

6/2/23 HYDR

Lukoil increases oil production at West Qurna 2 to 480,000 barrels per day

6/2/23 LKOH

Rostelecom's revenues reach ₽650 billion in 2022

6/2/23 RTKM

Moscow Exchange switches the stock market into a single mode of trading and settlements T+1

6/2/23 MOEX

Rosbank started testing cross-border payments in cryptocurrency

6/2/23 ROSB